Interleukin 28B Genotype and Insulin Resistance in Chronic Hepatitis C Patients. Issue 8 (November 2014)

• Record Type: Journal Article
• Authors: Degasperi, Elisabetta; Valenti, Luca; Aghemo, Alessio; De Francesco, Raffaele; Rumi, Mariagrazia; Soffredini, Roberta; Donnici, Lorena; Cheroni, Cristina; Fargion, Silvia; Zanoni, Valeria; Orsi, Emanuela; Colombo, Massimo
• Is Part Of: Antiviral therapy. Volume 19:Issue 8(2014)
• Page Start: 747
• Page End: 753
• Publication Date: 2014-11
• Subjects: Antiviral agents -- Periodicals; Antiviral Agents -- therapeutic use; Virus Diseases -- therapy; Viruses -- drug effects; Antiviral agents; Periodical; Electronic journals; Periodicals; 616.9106
• DOI: 10.3851/IMP2743
• Languages: English
• ISSNs: 1359-6535

Abstract

Background: In patients with chronic HCV infection, an association between IL28B genotype and insulin-resistance (IR), known predictors of sustained virological response (SVR) to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy, has been reported. The aim of this study was to investigate the association of IR and IL28B genotype in two cohorts of well-characterized HCV patients. Methods: A total of 480 non-diabetic HCV patients were analysed: 391 patients who received PEG-IFN/RBV in the MIST study and 89 previously reported patients followed at a metabolic liver diseases centre (Division of Internal Medicine, Fondazione IRCCS Ospedale Maggiore Policlinico, Milan, Italy). All were tested for IL28B rs12979860 single nucleotide polymorphism by real-time PCR and had IR measured by HOMA-IR. Staging of liver disease through liver biopsy was available for all patients. Results: Overall, 164 patients (34%) were IL28B CC. Mean HOMA-IR values (±sd ) did not differ according to IL28B genotype, being respectively 1.14 ±0.79 in CC versus 1.14 ±0.78 in CT/TT ( P =1.0) in the first, and 2.4 ±1.0 versus 2.5 ±1.0 (P=0.7) in the second cohort. HOMA-IR>2 was not associated with IL28B genotype: 16/132 (12%) CC versus 31/259 (12%) CT/TT ( P =1.0) in the first cohort and 16/32 (50%) versus 37/57 (65%; P =0.18) in the second. This held true also when using different HOMA cutoffs (>2.5, >3.0, >3.5 and >4.0). In the MIST cohort, HOMA-IR>2 did not influence treatment outcome, SVR rates being 28/47 (60%) in HOMA-IR>2 versus 214/344 (62%) in HOMA-IR≤2 ( P =0.8). IL28B genotype was a strong predictor of SVR: 84% (111/132) in CC versus 51% (131/259) in CT/TT patients ( P <0.0001). Conclusions: In two cohorts of non-diabetic HCV patients where IL28B genotype predicted treatment outcome, we found no association between IL28B genotype and HOMA-IR.